In the previous paper of this series “Making conjoint fit for pharma”, we discussed why traditional conjoint approaches overburden respondents in pharma market research. In this paper, we explore the impact of sample size on reliability, the challenges of recruiting enough respondents to drown out the noise, and how a fit-for-pharma conjoint platform solves these challenges.

Request the second paper here, or read the full series.